載入中
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
收盤時
US$16.46
−US$0.27 · -1.61%
盤後
US$16.21
−US$0.25 · -1.52%
10月12日 下午7:58 ET
盤中時間採用ET。市場資料可能有所延遲。
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
日內區間
目前US$16.46
52週區間
目前US$16.46
盤中時間採用ET。市場資料可能有所延遲。
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
日內區間
目前US$16.46
52週區間
目前US$16.46
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.53億 USD | 7900.4萬 USD | 6488.4萬 USD | 3043.3萬 USD | 643.4萬 USD |
| 銷售、一般及管理費用 | 2418.3萬 USD | 1530.4萬 USD | 970.6萬 USD | 647.3萬 USD | 226.2萬 USD |
| 營業費用 | 1.78億 USD | 9430.8萬 USD | 7459萬 USD | 3690.6萬 USD | 869.6萬 USD |
| 利息收入 | 1122.6萬 USD | 1382萬 USD | 525.7萬 USD | — | — |
| 折舊和攤銷 | — | — | — | 3690.6萬 USD | — |
| 營業利益 | −1.78億 USD | −9430.8萬 USD | −7459萬 USD | −3690.6萬 USD | −869.6萬 USD |
| 淨利 | −1.66億 USD | −8048.8萬 USD | −6933.3萬 USD | −3690.6萬 USD | −5160.6萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.00
上漲空間 33.66%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4022.99萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1654.36萬0.02%787.4億 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1513.04萬0.15%98.74億 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF1207.01萬0.01%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO654.45萬0.04%180億 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO582.73萬0.04%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB450.07萬0.04%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA367.97萬0.02%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
